Posted by Michael Wonder on 19 Jul 2022
Wugen receives US FDA fast track and rare paediatric disease designations for WU-CART-007 for the treatment of R/R T-ALL/LBL
19 July 2022 - Wugen, today announced that the U.S. FDA has granted fast track designation and rare paediatric disease designation for WU-CART-007, the company’s off the shelf CAR-T cell therapy.
WU-CART-007 is currently being explored for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma.
